Clinical Trials Logo

Familial Hyperchylomicronemia clinical trials

View clinical trials related to Familial Hyperchylomicronemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03293810 Completed - Clinical trials for Lipoprotein Lipase Deficiency

Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients

GENIALL
Start date: June 27, 2014
Phase:
Study type: Observational [Patient Registry]

Lipoprotein lipase deficiency (LPLD) is a rare autosomal recessive disorder, characterized by loss-of function mutations in the LPL gene, leading to the inability to produce functionally active lipoprotein lipase (LPL). LPL is the key enzyme in the metabolism of triglyceride (TG)-rich lipoproteins (chylomicrons (CM) and very low-density lipoproteins (VLDL)). LPLD results in extremely high concentrations of circulating TG-rich lipoproteins. No drug therapy for LPLD is currently available. Clinical management of LPLD patients consists of severe dietary fat restriction and the use of medium-chain triglycerides to substitute for normal dietary fats. Alipogene tiparvovec (Glybera®) received marketing authorisation from the European commission on 25 October 2012. Glybera® aims to correct lipoprotein lipase deficiency sufficiently to decrease the morbidity and lower the risk of inherent complications of LPLD, in adult patients genetically diagnosed with LPLD. The Glybera Registry is designed to collect the long-term safety and efficacy data of GLYBERA®